Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
Evaxion A/S - American Depositary Share (EVAX)
Company Research
Source: GlobeNewswire
New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune responseThe results reinforce that Evaxion’s pioneering AI platform, AI-Immunology™ accurately identifies and selects the most relevant vaccine targetsData will be presented at the American Association for Cancer Research (AACR) Annual Meeting COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating that AI-Immunology™ identifies and selects the most therapeutically relevant vaccine targets. The data will be presented at the AACR Annual Meeting in San Diego, California, on April 22, 2026. 86% of the vaccine targets included in Evaxion’s personalized cancer vaccine EVX-01 trigger a tumor-specific immune response. This is a success rate much higher than what has been reported for other met
Show less
Read more
Impact Snapshot
Event Time:
EVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVAX alerts
High impacting Evaxion A/S - American Depositary Share news events
Weekly update
A roundup of the hottest topics
EVAX
News
- Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial [Yahoo! Finance]Yahoo! Finance
- New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastomaGlobeNewswire
- Evaxion concludes Annual General MeetingGlobeNewswire
- Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01GlobeNewswire
- Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress [Yahoo! Finance]Yahoo! Finance
EVAX
Sec Filings
- 4/17/26 - Form 6-K
- 4/17/26 - Form 6-K
- 4/16/26 - Form 6-K
- EVAX's page on the SEC website